About this site
Idiopathic pulmonary fibrosis (IPF) is the most prevalent form of idiopathic interstitial pneumonia (IIP).6
It is a serious condition with a poor prognosis, having a worse 5-year survival rate than many common malignancies.2-5, 12
This educational initiative aims to bring IPF to the forefront and ensure that healthcare professionals are equipped with the knowledge and tools for the early identification, diagnosis and treatment of IPF, which may help improve the outcome of patients.
This programme is sponsored by Roche, a biotechnology company focused on the research, development and commercialisation of innovative therapies in pulmonology and orphan fibrotic diseases. For further information on Roche, please contact us.